MAP4K1 and breast cancer: Type IV is between Type II and III.30 A study suggested that the expression signature of ANXA10, DAB2, HYAL2, SCD1, and MAP4K1 could predict progression of T1G3 BC with the sensitivity of 79% and the specificity of 86%.31